Updates are available Correction dated 2024-10-22
Click to view Correction: https://doi.org/10.1186/s12967-024-05717-3
-
Authors
Pallocca, Matteo http://orcid.org/0000-0002-7756-3579
Molineris, Ivan
Berrino, Enrico
Marcozzi, Benedetta
Betti, Martina
Levati, Lauretta
D’Atri, Stefania
Menin, Chiara
Madonna, Gabriele
Ghiorzo, Paola
Bulgarelli, Jenny
Ferraresi, Virgina
Venesio, Tiziana
Rodolfo, Monica
Rivoltini, Licia
Lanfrancone, Luisa
Ascierto, Paolo Antonio
Mazzarella, Luca
Pelicci, Pier Giuseppe
De Maria, Ruggero
Ciliberto, Gennaro
Medico, Enzo
Russo, Giandomenico
-
Funding
Funding for this research was provided by:
Ministero della Salute (Ricerca Corrente)
- License Information
-
More Information
Article History
Received: 8 September 2023
Accepted: 28 November 2023
First Online: 6 January 2024
Change Date: 22 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12967-024-05717-3
Declarations
:
: The study was conducted according to the recommendations of the last revision of Helsinki Declaration, Oviedo Convention and Good Clinical Practices.
: Not applicable.
: All the authors declare no competing interests with the exception of P.A.A and MP. P.A.A has/had a consultant/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, DaiichiSankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune. P.A.A. also received research funding from Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi. Travel support by Pfizer. All outside the submitted work. M.P. acted as a consultant for Dexma srl, outside the scope of this work.
